Payment overview · 2025
General Payments
$1,551.15
77 reported records · 21 companies
Healthcare provider profile · identity verified
Alfred A Boyd, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHENANDOAH, TX · NPI 1295774339
Verified facts
What the public records show
CMS Open Payments records show Alfred A Boyd, MD received $1,551.15 in general payments during 2025 across 77 reported records.
Inspire Medical Systems, Inc. accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $277.79 | 17.9% | 12 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $223.78 | 14.4% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $190.43 | 12.3% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $187.05 | 12.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $147.35 | 9.5% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.53 | 4.4% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $58.82 | 3.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $43.24 | 2.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.90 | 2.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.45 | 2.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.61 | 2.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.89 | 2.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.85 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.25 | 1.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $24.18 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.93 | 1.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.69 | 1.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.42 | 1.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.01 | 1.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.40 | 1.2% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.58 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,551.15 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $277.79 | 12 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $223.78 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $139.06 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $122.39 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $114.16 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $94.65 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $73.27 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $58.82 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $52.70 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.37 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $47.26 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.90 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.08 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 545 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 365 | 128 |
| Lisinopril | Lisinopril | 326 | 107 |
| Losartan Potassium | Losartan Potassium | 276 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 101 |
| Gabapentin | Gabapentin | 230 | 90 |
| Metformin Hcl | Metformin Hcl | 229 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 173 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 59 |
| Allopurinol | Allopurinol | 147 | 50 |
| Simvastatin | Simvastatin | 144 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 141 | 54 |
| Trazodone Hcl | Trazodone Hcl | 141 | 61 |
| Furosemide | Furosemide | 134 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 31 |
| Omeprazole | Omeprazole | 114 | 45 |
| Alprazolam | Alprazolam | 107 | 24 |
| Meloxicam | Meloxicam | 103 | 37 |
| Sertraline Hcl | Sertraline Hcl | 101 | 40 |
| Montelukast Sodium | Montelukast Sodium | 97 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 36 |
| Prednisone | Prednisone | 91 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 52 |
| Famotidine | Famotidine | 82 | 31 |
| Bupropion Xl | Bupropion Hcl | 80 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 21 |
| Metformin Hcl Er | Metformin Hcl | 78 | 31 |
| Finasteride | Finasteride | 74 | 23 |
| Donepezil Hcl | Donepezil Hcl | 67 | 23 |
| Valsartan | Valsartan | 66 | 27 |
| Carvedilol | Carvedilol | 64 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 50 |
| Potassium Chloride | Potassium Chloride | 63 | 25 |
| Tramadol Hcl | Tramadol Hcl | 63 | 19 |
| Alendronate Sodium | Alendronate Sodium | 61 | 19 |
| Atenolol | Atenolol | 55 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 23 |
| Azithromycin | Azithromycin | 54 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 17 |
| Celecoxib | Celecoxib | 52 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 21 |
| Ozempic | Semaglutide | 51 | 12 |
| Nifedipine Er | Nifedipine | 50 | 17 |
| Glipizide | Glipizide | 49 | 15 |
| Lovastatin | Lovastatin | 49 | 12 |
| Synthroid | Levothyroxine Sodium | 49 | 15 |
| Ezetimibe | Ezetimibe | 48 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 13 |
| Clonazepam | Clonazepam | 46 | 17 |
| Eliquis | Apixaban | 46 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 14 |
| Trulicity | Dulaglutide | 44 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 11 |
| Mounjaro | Tirzepatide | 41 | 16 |
| Januvia | Sitagliptin Phosphate | 40 | 12 |
| Buspirone Hcl | Buspirone Hcl | 39 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 12 |
| Valacyclovir | Valacyclovir Hcl | 37 | 18 |
| Fenofibrate | Fenofibrate | 36 | 12 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 13 |
| Glimepiride | Glimepiride | 33 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 13 |
| Mirtazapine | Mirtazapine | 33 | 15 |
| Pregabalin | Pregabalin | 33 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Estradiol | Estradiol | 32 | 11 |
| Ondansetron Odt | Ondansetron | 32 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 17 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Jardiance | Empagliflozin | 29 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 13 |
| Acyclovir | Acyclovir | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Linzess | Linaclotide | 26 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 11 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Baclofen | Baclofen | 23 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 21 | 13 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Etodolac | Etodolac | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,551.15 · 77 records | Inspire Medical Systems, Inc. | AIRSUPRA, AREXVY, CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, Flector, GARDASIL 9, GVOKE HYPOPEN, INSPIRE, JARDIANCE, LAGEVRIO, Leqembi, Licart, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, TZIELD, Tirosint, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error